Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group.
作者信息
D'Angiò Mariella, Valsecchi Maria G, Testi Anna M, Conter Valentino, Nunes Vittorio, Parasole Rosanna, Colombini Antonella, Santoro Nicola, Varotto Stefania, Caniglia Maurizio, Silvestri Daniela, Consarino Caterina, Levati Laura, Magrin Elisa, Locatelli Franco, Basso Giuseppe, Foà Robin, Biondi Andrea, Cazzaniga Gianni
机构信息
Department of Cellular Biotechnologies and Hematology, University Sapienza, Roma.
Center of Biostatistics for Clinical Epidemiology, Department of Health Sciences, University of Milano-Bicocca, Milano.
出版信息
Haematologica. 2015 Jan;100(1):e10-3. doi: 10.3324/haematol.2014.112151. Epub 2014 Oct 10.
Abstract
摘要
相似文献
1
Clinical features and outcome of SIL/TAL1-positive T-cell acute lymphoblastic leukemia in children and adolescents: a 10-year experience of the AIEOP group.
Haematologica. 2015 Jan;100(1):e10-3. doi: 10.3324/haematol.2014.112151. Epub 2014 Oct 10.
2
Immunophenotyping with CD135 and CD117 predicts the FLT3, IL-7R and TLX3 gene mutations in childhood T-cell acute leukemia.
Blood Cells Mol Dis. 2016 Mar;57:74-80. doi: 10.1016/j.bcmd.2015.12.003. Epub 2015 Dec 2.
3
SIL-TAL1 fusion gene negative impact in T-cell acute lymphoblastic leukemia outcome.
Leuk Lymphoma. 2009 Aug;50(8):1318-25. doi: 10.1080/10428190903040014.
4
TRIB2 reinforces the oncogenic transcriptional program controlled by the TAL1 complex in T-cell acute lymphoblastic leukemia.
Leukemia. 2016 Apr;30(4):959-62. doi: 10.1038/leu.2015.195. Epub 2015 Jul 23.
5
Translocation t(8;14)(q24;q11) with concurrent PTEN alterations and deletions of STIL/TAL1 and CDKN2A/B in a pediatric case of acute T-lymphoblastic leukemia: A genetic profile associated with adverse prognosis.
Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26266. Epub 2016 Oct 19.
6
[Clinical Characteristics and Treatment Efficacy of Children with SIL/TAL1 Positive T-Cell Acute Lymphoblastic Leukemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Jun;24(3):681-6. doi: 10.7534/j.issn.1009-2137.2016.03.008.
7
Clinical characterization and prognosis of T cell acute lymphoblastic leukemia with high CRLF2 gene expression in children.
PLoS One. 2019 Dec 12;14(12):e0224652. doi: 10.1371/journal.pone.0224652. eCollection 2019.
8
Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia.
Cancer Cell. 2012 Aug 14;22(2):209-21. doi: 10.1016/j.ccr.2012.06.007.
9
Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
J Immunother Cancer. 2020 May;8(1). doi: 10.1136/jitc-2020-000630.
10
[Clinical features of 19 patients with SIL-TAL1-positive T-cell acute lymphoblastic leukemia].
Zhonghua Xue Ye Xue Za Zhi. 2023 Feb 14;44(2):132-136. doi: 10.3760/cma.j.issn.0253-2727.2023.02.008.
引用本文的文献
1
Towards methylation-based redefinition of TAL1 positive T-cell acute lymphoblastic leukaemia (T-ALL).
Leukemia. 2025 Aug 8. doi: 10.1038/s41375-025-02714-3.
2
T-cell acute lymphoblastic leukaemia: subtype prevalence, clinical outcome, and emerging targeted treatments.
Leukemia. 2025 Apr 17. doi: 10.1038/s41375-025-02599-2.
3
SIL-TAL1-Positive Adult T-ALL with t(11;14)(p15;q11.2): A Rare Case Report Highlighting Prognostic Challenges and Treatment Implications.
J Inflamm Res. 2025 Feb 17;18:2339-2347. doi: 10.2147/JIR.S497615. eCollection 2025.
4
Concurrent peripheral T-cell lymphoma and T-cell lymphoblastic leukemia/lymphoma with identical :: fusion events.
Haematologica. 2024 Mar 1;109(3):994-999. doi: 10.3324/haematol.2023.283585.
5
Proteomics in Childhood Acute Lymphoblastic Leukemia: Challenges and Opportunities.
Diagnostics (Basel). 2023 Aug 24;13(17):2748. doi: 10.3390/diagnostics13172748.
6
S1P-S1PR3-RAS promotes the progression of S1PR3 TAL1 T-cell acute lymphoblastic leukemia that can be effectively inhibited by an S1PR3 antagonist.
Leukemia. 2023 Oct;37(10):1982-1993. doi: 10.1038/s41375-023-02000-0. Epub 2023 Aug 17.
7
Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia.
Cancers (Basel). 2023 Jan 6;15(2):374. doi: 10.3390/cancers15020374.
8
Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.
Mol Cancer. 2023 Jan 18;22(1):12. doi: 10.1186/s12943-022-01701-x.
9
A Case of -positive T-lymphoblastic Leukemia With a Minor Philadelphia-positive Clone.
Ann Lab Med. 2023 Jan 1;43(1):100-103. doi: 10.3343/alm.2023.43.1.100. Epub 2022 Sep 1.
10
Clinico-Hematological Profile and Copy Number Abnormalities in a Cohort of and Positive Pediatric T-Cell Acute Lymphoblastic Leukemia.
Indian J Hematol Blood Transfus. 2021 Oct;37(4):555-562. doi: 10.1007/s12288-020-01394-6. Epub 2021 Jan 25.
本文引用的文献
1
Linking genomic lesions with minimal residual disease improves prognostic stratification in children with T-cell acute lymphoblastic leukaemia.
Leuk Res. 2013 Aug;37(8):928-35. doi: 10.1016/j.leukres.2013.04.005. Epub 2013 Jun 2.
2
Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.
Blood. 2011 Aug 25;118(8):2077-84. doi: 10.1182/blood-2011-03-338707. Epub 2011 Jun 30.
3
Modern therapy of acute lymphoblastic leukemia.
J Clin Oncol. 2011 Feb 10;29(5):532-43. doi: 10.1200/JCO.2010.30.1382. Epub 2011 Jan 10.
4
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia.
Leukemia. 2010 Feb;24(2):255-64. doi: 10.1038/leu.2009.250. Epub 2009 Dec 17.
5
SIL-TAL1 fusion gene negative impact in T-cell acute lymphoblastic leukemia outcome.
Leuk Lymphoma. 2009 Aug;50(8):1318-25. doi: 10.1080/10428190903040014.
6
Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
Haematologica. 2008 Nov;93(11):1658-65. doi: 10.3324/haematol.13291. Epub 2008 Oct 2.
7
8
Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and of SIL-TAL fusion in childhood T-cell malignancies: results of EORTC studies 58881 and 58951.
Blood. 2004 Jan 15;103(2):442-50. doi: 10.1182/blood-2003-05-1495. Epub 2003 Sep 22.
9
Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia.
Br J Haematol. 2002 Sep;118(4):1011-8. doi: 10.1046/j.1365-2141.2002.03747.x.
10
Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia.
Leukemia. 1999 Jan;13(1):110-8. doi: 10.1038/sj.leu.2401245.
Zotero 插件